Tamborero, David
Dienstmann, Rodrigo
Rachid, Maan Haj http://orcid.org/0000-0002-6380-209X
Boekel, Jorrit
Baird, Richard http://orcid.org/0000-0001-7071-6483
Braña, Irene
De Petris, Luigi
Yachnin, Jeffrey
Massard, Christophe
Opdam, Frans L.
Schlenk, Richard
Vernieri, Claudio
Garralda, Elena
Masucci, Michele
Villalobos, Xenia
Chavarria, Elena
Anand, Shubha
Azaro, Analía
Baars, Danny
Bajalica-Lagercrantz, Svetlana
Balmaña, Judith
Bergh, Jonas
Bierkens, Mariska
Blomqvist, Lennart
Doherty, Gary J.
Forest, Arnauld
Fornerone, Valentina
Funingana, Ionut Gabriel
Gabaldi, Paola
Hartman, Johan
Horak, Peter
Karlsson, Claes
Kasanicki, Mary
Kreutzfeldt, Simon
Lewensohn, Rolf
Lindberg, Johan
Lopez, Carlos
Lundqvist, Andreas
Martin-Romano, Patricia
Martin, Jose-Ezequiel
Meijer, Gerrit
Muñoz, Susana
Camus, Maud Ngo
Nicotra, Claudio
Nuciforo, Paolo
Oberrauch, Petra
Östling, Päivi
Piris-Giménez, Alejandro
Provenzano, Elena
Rouleau, Etienne
Rowell, John
Saavedra, Omar
Valdivia, Ignacio Sánchez
Scoazec, Giovanni
Seamon, Kenneth
Tischkowitz, Marc
van der Kolk, Lizet
van der Noll, Ruud
Vis, Daniel
Vivancos, Ana
von Gertten, Christina
Wennborg, Anders
Wessels, Lodewyk
Wirta, Valtteri
Wolfart, Julia
Calvo, Fabien
Fröhling, Stefan http://orcid.org/0000-0001-7907-4595
Eggermont, Alexander
Apolone, Giovanni
Voest, Emile E. http://orcid.org/0000-0001-8249-9586
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Ernberg, Ingemar
Rodon, Jordi
Lehtiö, Janne http://orcid.org/0000-0002-8100-9562
,
Article History
First Online: 6 July 2020
Competing interests
: D. T. reports consultant and/or advisory fees from Roche. R. D. reports receiving honoraria for speaker activities from Roche, Ipsen, Amgen, Sanofi, Servier Laboratories and Merck Sharp & Dohme; an advisory role at Roche and Boehringer Ingelheim; and research grants from Merck and Pierre Fabre. R. B. reports consultant or advisory roles (with funding to the institution) at AstraZeneca, Daiichi-Sankyo, Lilly, Molecular Partners, Novartis, Roche and Shionogi; is a principal or sub-investigator of clinical trials for Astex, AstraZeneca, Boehringer-Ingelheim, Boston Therapeutics, Genentech/Roche, Johnson & Johnson, Lilly, Molecular Partners, PharmaMar, Roche, Sanofi-Aventis, Shionogi and Taiho; and reports research grants from AstraZeneca, Boehringer-Ingelheim and Genentech. I. B. reports a consultant or advisory role at Orion Pharma and speaker activities for Bristol Myers Squibb; reports travel grants from AstraZeneca and Merck Serono; and is a principal investigator of clinical trials for AstraZeneca, Bristol Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen, Kura, Merck, Sharp & Dohme, Novartis, Orion Pharma, Pfizer, Shattuck, Northern Biologics, Rakutan Aspirian and Nanobiotics. C. M. reports consultant and/or advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck, Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, Orion; and is a principal or sub-investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, Merck, Sharp & Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro and Xencor. R. S. reports research funding from Pfizer, AstraZeneca, PharmaMar, Roche and Daiichi Sankyo; speaker honoraria from Pfizer, Daiichi Sankyo and Novartis; and participation in advisory boards at Pfizer, Daiichi Sankyo and Novartis. E. G. reports consultant honoraria from Roche/Genentech, F. Hoffmann La Roche, Ellipses Pharma, Neomed Therapeutics, Boehringer Ingelheim–Janssen Global Services, AstraZeneca, SeaGen, TFS–Alkermes; reports research for Novartis/Roche; is a principal or sub-investigator of clinical trials for Principia Biopharma, Lilly, Novartis Farmacéutica, Genentech, Loxo Oncology, F. Hoffmann La Roche, Symphogen, Merck, Sharp & Dohme de España, Incyte Biosciences International, Pharma Mar, Kura Oncology, Macrogenics, Glycotope, Pierre Fabre Medicament, Cellestia Biotech, Menarini Ricerche Spa, Blueprint Medicines, Beigene Usa, Sierra Oncology and Genmab; reports travel grants from Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope; and is on the speakers bureau for Bristol-Mayers Squibb, Merck Sharp & Dohme, Roche and ThermoFisher. S. F. reports a consulting or advisory role, having received honoraria, research funding, and/or travel/accommodation expenses funding from Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. A. E. has received personal fees from Actelion, Agenus, Amgen, Bayer, Bristol Myers Squibb, Catalym, CellDex, Gilead, GlaxoSmithKline, HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Nektar, Novartis, Pfizer, Polynoma, Regeneron, Sanofi and SkylineDx; and has equity in RiverDx, SkylineDx and Theranovir. E. E. V. is legally responsible for all contracts with pharmaceutical companies, as medical director of the Netherlands Cancer Institute. C. C. is a member of the External Science Panel of AstraZeneca and of Illumina’s Scientific Advisory Board, and his laboratory has received research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. J. T. provides a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab, Halozyme, Imugene, Inflection Biosciences, Ipsen, Kura Oncology, Lilly, Merck Sharp & Dohme, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign, Rafael Pharmaceuticals, F. Hoffmann La Roche, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. J. R. reports research funding from Bayer & Novartis; clinical research for Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millennium, GlaxoSmithKline and Ipsen; is on the scientific advisory board of Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceuticals/Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma; and reports research funding for Bayer & Novartis. J. L. reports research funding from AstraZeneca, Novartis and GE healthcare; and is a co-founder and shareholder of FenoMark Diagnostics.